Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltrationMarko Škrtić, David Z.I. Cherney, Gary K. Yang et al.|Diabetologia|2014Cited by 162
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme InhibitionYuliya Lytvyn, David Z.I. Cherney, Nuala Peter et al.|Circulation|2022Cited by 69
Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney functionErik J.M. van Bommel, Daniël H. van Raalte, Yuliya Lytvyn et al.|Kidney International|2020Cited by 46
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trialLorraine B. Ware, Tobias Welte, Nima Soleymanlou et al.|Thorax|2023Cited by 9
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltrationMarko Škrtić, David Z.I. Cherney, Gary K. Yang et al.|Diabetologia|2017Cited by 0